As an attending hematopathologist I am involved in diagnostic work up and follow up after therapy of patients diagnosed with hematologic malignancies including AML, ALL, MDS and MDS/MPN. I am interested in understanding the pathogenesis of hematopoietic tumors and how specific events required for leukemic transformation can be targeted for therapy. In addition, as part of collaborative research projects I have been involved in the analyses of mice in models of normal and malignant hematopoiesis.
Department of Pathology, Univeristy of Chicago
Chicago
Fellowship - Hematopathology
2008
Department of Pathology, Univeristy of Chicago
Chicago
Residency - Clinical Pathology
2007
Ben May Department of Cancer Research, University of Chicago
Chicago
Post Doctoral Fellowship - Cancer Biology, Normal and Malignant Hematopoiesis
2004
INSERM U517, University of Burgundy
Dijon, France
Post Doctoral Fellowship - Cancer Biology, Apoptosis
2002
All India Institute of Medical Sciences
New Delhi, India
PhD - Hematology
2000
Motilal Nehru Medical College
Allahabad, India
MBBS - Medicine
1992
Microbiota does not influence tumor development in two models of heritable cancer.
Microbiota does not influence tumor development in two models of heritable cancer. mBio. 2025 Mar 12; 16(3):e0386624.
PMID: 39969175
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies.
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies. Hemasphere. 2025 Feb; 9(2):e70083.
PMID: 39897085
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
PMID: 39866945
PHF6 suppresses self-renewal of leukemic stem cells in AML.
PHF6 suppresses self-renewal of leukemic stem cells in AML. Leukemia. 2024 Sep; 38(9):1938-1948.
PMID: 39004675
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
Malignant progression of preleukemic disorders.
Malignant progression of preleukemic disorders. Blood. 2024 05 30; 143(22):2245-2255.
PMID: 38498034
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
PMID: 38150184
SETBP1 sets the stage.
SETBP1 sets the stage. Blood. 2024 04 04; 143(14):1323-1324.
PMID: 38573606
PHF6 suppresses self-renewal of leukemic stem cells in AML.
PHF6 suppresses self-renewal of leukemic stem cells in AML. bioRxiv. 2024 Jan 18.
PMID: 38260439
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510